Vittorio D Ferrari
Overview
Explore the profile of Vittorio D Ferrari including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
13
Citations
114
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Tovazzi V, Ferrari V, Berruti A
Endocrine
. 2021 Jan;
71(1):258.
PMID: 33442791
No abstract available.
2.
Dalla Volta A, Valcamonico F, Zamboni S, Ferrari V, Grisanti S, Simeone C, et al.
Minerva Urol Nefrol
. 2020 Oct;
72(6):778-779.
PMID: 33016032
No abstract available.
3.
Tovazzi V, Ferrari V, Dalla Volta A, Consoli F, Amoroso V, Berruti A
Endocrine
. 2020 Jun;
69(3):481-484.
PMID: 32488839
Insulinoma is a rare pancreatic neuroendocrine tumor (pNET) potentially associated with severe hypoglycaemic crisis. The great majority of these tumors are benign. In patients with metastatic malignant insulinoma, systemic therapies...
4.
Cosentini D, Badalamenti G, Grisanti S, Basile V, Rapa I, Cerri S, et al.
Eur J Endocrinol
. 2019 Oct;
181(6):681-689.
PMID: 31639772
Objective: Temozolomide has shown a significant anti-proliferative activity on adrenocortical cancer (ACC) cells in vitro. Design: On the basis of these results the drug was prescribed as second/third line in...
5.
Fornaro C, Piubeni M, Tovazzi V, Cosentini D, Gelmi M, Rota G, et al.
Eur J Cancer Care (Engl)
. 2018 Dec;
28(2):e12978.
PMID: 30536872
Port-a-cath (PAC) system is one of the most frequently employed venous accesses for administration of chemotherapy and supportive care. To prevent late complications, the latest guidelines recommend flushing/locking procedures every...
6.
Grisanti S, Cosentini D, Tovazzi V, Bianchi S, Lazzari B, Consoli F, et al.
Support Care Cancer
. 2018 Mar;
26(8):2929-2935.
PMID: 29546526
Purpose: Trabectedin is one of the few active agents in soft tissue sarcoma (STS) but hepatotoxicity is frequent and represents a dose-limiting factor. Protective strategies aiming at counteracting this important...
7.
Grisanti S, Ferrari V, Buglione M, Agazzi G, Liserre R, Poliani L, et al.
J Neurosurg Sci
. 2016 Sep;
63(4):458-467.
PMID: 27680966
Introduction: Second line treatment of recurrent or progressive glioblastoma multiforme (GBM) is not standardized. Anti-angiogenic strategies with tyrosine-kinase inhibitors have been tested with conflicting results. We tested the association of...
8.
Grisanti S, Almici C, Consoli F, Buglione M, Verardi R, Bolzoni-Villaret A, et al.
PLoS One
. 2014 Aug;
9(8):e103918.
PMID: 25105871
Introduction: We investigated the frequency of detection and the prognostic and predictive significance of circulating tumor cells (CTCs) in patients with recurrent/metastatic (R/M) head and neck carcinoma (HNC) before starting...
9.
Grisanti S, Amoroso V, Buglione M, Rosati A, Gatta R, Pizzocaro C, et al.
J Med Case Rep
. 2008 Oct;
2:320.
PMID: 18826647
Introduction: Patients with metastatic mucoepidermoid carcinoma of salivary glands have a poor outcome. The epidermal growth factor receptor protein is overexpressed in approximately 70% of mucoepidermoid carcinoma patients and may...
10.
Amoroso V, Pittiani F, Grisanti S, Valcamonico F, Simoncini E, Ferrari V, et al.
BMC Cancer
. 2007 Jun;
7:94.
PMID: 17540044
Background: The RECIST guidelines are commonly used in phase II and III clinical trials. The correct definition of response can be controversial in some situations, as in the case we...